AUA Annual Meeting | Conferences

Darolutamide OS Stands Up to Other Approved Drugs for the nmCRPC

June 28, 2020

In an interview with Targeted Oncology, Neal Shore, MD, director, Carolina Urologic Research Center, discussed the OS analysis for the phase 3 ARAMIS study and explained a match-adjusted indirect comparison. He also discussed how these data connect with presentations around the 3 approved agents for nmCRPC being presented at AUA 2020.

Promising Efficacy and Safety With Seleno-L-Methionine Plus Axitinib in ccRCC

May 16, 2020

Yousef Zakharia, MD, discussed recent phase I data from a study of seleno-L-methionine in combination with axitinib as treatment of patients with previously treated or relapsed clear cell renal cell carcinoma. Zakharia recently presented these data as part of the American Urological Association Virtual Experience platform for the 2020 AUA Annual Meeting.

Clinical Activity With Pembrolizumab/Enzalutamide Emboldens Further Study in mCRPC

May 15, 2020

Positive safety and efficacy outcomes were witnessed in the KEYNOTE-365 study , supporting further assessment of the combination of pembrolizumab and enzalutamide in a larger population of patients with metastatic castration resistance prostate cancer.

Neoadjuvant Apalutamide Leads to Reduced Tumor Volume in High-Risk Prostate Cancer

May 15, 2020

"Historically, neoadjuvant hormone therapy has been shown to improve pathologic outcomes. Therefore, neoadjuvant androgen deprivation therapy may allow a nerve-sparing surgical approach to increase post-surgical quality-of-life outcomes without compromising oncologic outcomes.”